ImmunityBio 2025 Q3 Earnings Revenue Surges 433.8% as Net Loss Narrows by 21.5%

ImmunityBio (NASDAQ: IBRX) reported Q3 2025 earnings on Nov 6, 2025, showcasing a 433.8% year-over-year revenue surge to $31.78 million, driven by strong demand for its flagship product, ANKTIVA. , a 21.5% improvement from $85.75 million in Q3 2024. Despite the revenue growth, persistent R&D and SG&A expenses kept the company unprofitable, .

Revenue

Product revenue, net, , contributing to a total revenue of $32.06 million, . This 433.8% year-over-year growth reflects robust adoption of ANKTIVA in bladder cancer treatment and expanding market access.

Earnings/Net Income

, , . Despite these gains, sustained losses over 12 consecutive quarters underscore the need for further cost optimization and revenue diversification to achieve profitability.

Post-Earnings Price Action Review

Following the earnings release, , with a 10.17% drop over the past week and a 15.20% monthly slump. The mixed performance reflects investor skepticism about the company’s path to profitability, despite revenue momentum and clinical progress.

Additional News

1. UK MHRA Approval: ImmunityBio secured UK approval for ANKTIVA in bladder cancer treatment, marking its first international authorization.

2. Clinical Trial Advances: Promising data from glioblastoma and NSCLC trials, including 100% disease control in 5 GBM patients, reinforced ANKTIVA’s therapeutic potential.

3. Shareholder Reforms: A court-approved settlement added an independent director to ImmunityBio’s board, addressing governance concerns and strengthening investor confidence.